This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutIntroducing Enbrel®Heritage of Enbrel®IndicationsTherapeutic IndicationsRheumatoid ArthritisJuvenile Idiopathic ArthritisPsoriatic ArthritisAxial SpondyloarthritisPsoriasis & Paediatric PsoriasisMechanism of actionMode of ActionHalf-lifeDosingDosingRheumatoid Arthritis, Psoriatic Arthritis & Axial SpondyloarthritisJuvenile Idiopathic ArthritisPsoriasisPaediatric PsoriasisAdministration & StorageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid EffectivenessSustained EffectivenessEffectiveness With Monotherapy or Combination TherapySafetyTolerability Across IndicationsSummary of Prescribing InformationImmunogenicityImmunogenicity & Clinical ResponseImmunogenicity & Enbrel®Experience & InsightsExperience & InsightManufacturingPatient StoriesRheumatoid ArthritisPatient With an Increased Risk of Serious InfectionsMTX-IR PatientPatient Who Is Considering Starting a FamilyElderly-onset RA PatientYoung Patient Worried About the Lifelong Impact of RAYoung Patient Worried About Treatments That Lose Effectiveness Over TimeJuvenile Idiopathic ArthritisJuvenile PatientPatient Moving From Childhood to AdolescenceAxial SpondyloarthritisAS Patients With Heel EnthesitisAS Patients With Functional LimitationsAdvanced AS PatientsPsoriatic Arthritis & PsoriasisPsO Patient With Severe SymptomsPsO Patients With Cyclical SymptomsPsA Patient With Metabolic SyndromePsA Patient With Multiple Skin & Joint SymptomsSupport & ServicesSupport & ServicesUsing Enbrel®Summary of Prescribing InformationPatient ResourcesEventsMaterialsVideos

Juvenile Idiopathic Arthritis

Enbrel® is approved across 6 indications, including paediatric indications.¹

   

RF± polyarthritis and extended oligoarthritis

  • Enbrel® is indicated for the treatment of pJIA (RF±) and eoJIA in children aged 2 years and above and in adolescents1
Psoriatic arthritis
  • Enbrel® is indicated for the treatment of PsA in adolescents aged ≥12 years who have had an inadequate response to, or who have proven intolerance to, MTX1
Enthesitis-related arthritis
  • Enbrel® is indicated for the treatment of ERA in adolescents aged ≥12 years who have had an inadequate response to, or who have proven intolerance to, conventional therapy1
Enbrel® has not been studied in children aged <2 years.1

    

  • JIA is a heterogeneous group of conditions which encompasses all forms of arthritis of unknown aetiology lasting for at least 6 weeks and with onset before the age of 16 years2
  • Most common complications of JIA are leg-length discrepancy and joint contracture while an extremely fearsome complication is the macrophage activation syndrome3
  • Other important complications include growth retardation, low bone mineral density for chronologic age, severe hip involvement with the need of hip prosthesis and amyloidosis3
  • Etanercept provided sustained clinical benefit when used for up to 4 years in patients with JIA. ACR Pedi 30 scores at Year 1 were sustained through Year 4 of treatment with etanercept4

    

Safety and efficacy of etanercept in JIA after 13 years of treatment5

    

    Adapted from Bang MH, et al. 2019.
  • Drug survival rate after 13 years5:
     
    • 31% in systemic onset JIA patients
       
    • 84% in extended oligoarticular subtype
       
  • Drug survival after 10 years
     
    • 100% in RF+ polyarticular subtype
       
    • 80% in RF- polyarticular subtype
       
  • Drug survival after 5 years
     
    • 100% in ERA

Only 6 serious AEs (6.7%) during the 13-year period5

  

Retrospective data from 90 patients, 38 (42.0%) were male and 52 (58.0%) were female; 15 (16.7%) had systemic onset JIA, 41 (45.6%) had eoJIA, 14 (15.6%) had RF+ pJIA, 18 (20.0%) had RF− pJIA and 2 (2.1%) had ERA. Median age at the start of etanercept treatment was 9 years (range, 3-18 years), median duration of etanercept treatment was 6 years (range, 0.5-13 years).

  

 Vishala

A very young JIA patient

 Meet Vishala Dhruv

A JIA patient transitioning from childhood to adolescence

 Meet Dhruv

  

ACR Pedi, American College of Rheumatology Pediatric; AE, adverse event; eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PsA, psoriatic arthritis; pJIA, polyarticular juvenile idiopathic arthritis; RF+, rheumatoid factor positive; RF−, rheumatoid factor negative; RF±, rheumatoid factors positive or negative.

  

References:

Enbrel. Local product document. Version LPDENB062021.Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3(2):187-207.Thatayatikom A, Modica R, De Leucio A. Juvenile Idiopathic Arthritis. StatPearls [Internet]. Accessed May 5, 2022. https://www.ncbi.nlm.nih.gov/books/NBK554605/Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54(6):1987-1994.Bang MH, Kim KN. Long-term safety and efficacy of etanercept in juvenile idiopathic arthritis in a single center. J Rheum Dis 2019;26:200-205.

  

Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

    

PP-ENB-IND-0814 August 2022

    
Therapeutic Indications
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ENB-IND-0814

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023